News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche’s EPO Fails To Help Heart Attack Victims In Study
March 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ORLANDO, Fla., March 30 (Reuters) - High doses of erythropoietin, which boosts red blood cells, failed to improve the heart's pumping function in a study of heart attack victims, while its use also raised safety concerns.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Roche
MORE ON THIS TOPIC
Pancreatic cancer
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution
June 18, 2026
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Biogen makes up to $1B immuno play with RayThera takeover
June 18, 2026
·
2 min read
·
Tristan Manalac
Deals
Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B
June 17, 2026
·
2 min read
·
Gabrielle Masson
Huntington’s disease
UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again
June 17, 2026
·
4 min read
·
Heather McKenzie
